Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP627217.RAC1BBBX9pYAKcenokdhksF1sktM-GQ9lz1FvqfkBLMwI130_assertion description "[The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP627217.RAC1BBBX9pYAKcenokdhksF1sktM-GQ9lz1FvqfkBLMwI130_provenance.
• NP754602.RAQ5aojd0dOYfrAgICh2crH9BZ8eLCVPy0C3Mg7gG8bLs130_assertion description "[The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754602.RAQ5aojd0dOYfrAgICh2crH9BZ8eLCVPy0C3Mg7gG8bLs130_provenance.
• assertion description "[The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP428181.RAHA7J-5m6nh6Uj80FavEn0zDtBwRrXHEc9DgfHSqlKeE130_assertion description "[The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP428181.RAHA7J-5m6nh6Uj80FavEn0zDtBwRrXHEc9DgfHSqlKeE130_provenance.
• NP589151.RAwTi31tenwJuhuo7w_No8M6G9nghJkgVJ2M8hya6EbaI130_assertion description "[The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP589151.RAwTi31tenwJuhuo7w_No8M6G9nghJkgVJ2M8hya6EbaI130_provenance.
• assertion description "[The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP311487.RAdVQEWUjdjT2bB5knryOl5CA3AD2-bd2FvBOZ-LJRxEE130_assertion description "[The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP311487.RAdVQEWUjdjT2bB5knryOl5CA3AD2-bd2FvBOZ-LJRxEE130_provenance.
• NP311633.RAaks5WbkYVhLRWDmmgtrxldK1uJDb_Bgd_TMDMDcM_jw130_assertion description "[The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP311633.RAaks5WbkYVhLRWDmmgtrxldK1uJDb_Bgd_TMDMDcM_jw130_provenance.
• NP677112.RA2Vu1K77ZfHByIVMmpwDSt1_1kvBUGjI-iPJzaKUfneI130_assertion description "[The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP677112.RA2Vu1K77ZfHByIVMmpwDSt1_1kvBUGjI-iPJzaKUfneI130_provenance.
• NP311395.RAhX72DwOpEkZ9abedkD25FxBFnVQ98s-cBD-wbVippK0130_assertion description "[The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP311395.RAhX72DwOpEkZ9abedkD25FxBFnVQ98s-cBD-wbVippK0130_provenance.
• NP425555.RAWnrvOtAoWY2XS5ctM0ssjxQjKdZofLJUxwclJdGRadQ130_assertion description "[The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP425555.RAWnrvOtAoWY2XS5ctM0ssjxQjKdZofLJUxwclJdGRadQ130_provenance.
• NP425553.RApBFPpsOxBxlddYA9BxJGs9PenNWmFg6ZA9gl5TLOOPA130_assertion description "[The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP425553.RApBFPpsOxBxlddYA9BxJGs9PenNWmFg6ZA9gl5TLOOPA130_provenance.
• NP425556.RAv6DB5Qh30FrbDLo3X_cqgRC8DxcjDejUf01_ifWWb5Q130_assertion description "[The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP425556.RAv6DB5Qh30FrbDLo3X_cqgRC8DxcjDejUf01_ifWWb5Q130_provenance.
• NP311158.RA8HPE3GS5O55_a0ITfiu_T7LrO-SVKYOTN631ImzIs9I130_assertion description "[The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP311158.RA8HPE3GS5O55_a0ITfiu_T7LrO-SVKYOTN631ImzIs9I130_provenance.
• NP425551.RAGzRrNxIeMdArzHqxgcZrmFy5P7j5YHhmFQCTS_fNc4Y130_assertion description "[The CFTR 5T polymorphism was identified in 31 of 334 (9.3%) patients of sporadic pancreatic cancer, in 5 of 43 (11.6%) patients with familial pancreatic cancer and in 10 of 112 (8.9%) controls with colorectal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP425551.RAGzRrNxIeMdArzHqxgcZrmFy5P7j5YHhmFQCTS_fNc4Y130_provenance.